Davita Inc (DVA) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Davita Inc   (NYSE: DVA)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare


Davita Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Davita Inc 's ROA in the third quarter of 2026?
Davita Inc achieved a return on average assets (ROA) of 6.63 % in its third quarter of 2026, this is above DVA's average return on assets of 5.14%.
Davita Inc s assets during the 12 months ending in the third quarter of 2026 are valued at $17 billion

ROA decreased relative to the period ending Jun 30 2026, due to the decline in net income.

However, within the Healthcare sector 132 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 976, from total ROA ranking in the second quarter of 2026 at 1159.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Total Assets Change 1.23 % 0.98 % 3.2 % 18.42 % 16.36 %
Y / Y Net Income Change -7.21 % 24.71 % 18.44 % -5.22 % -18.77 %
Net Income (TTM) in million 1,172 1,190 1,122 1,079 1,097
Return On Assets (TTM) 6.63 % 6.75 % 6.38 % 6.18 % 6.54 %
DVA's Total Ranking # 976 # 1159 # 988 # 944 # 923
Total Assets (TTM) in million 17,771 17,665 17,667 17,637 17,556
Seq. Total Assets Change 0.6 % -0.01 % 0.17 % 0.46 % 0.36 %
Seq. Net Income Change -35.05 % 24.79 % -16.92 % 37.79 % -12.71 %

DVA's 5 Years Annual ROA >> Back to DVA Management Effectiveness >> Compare DVA ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 16
Sector # 133
Overall # 933

Return On Assets Statistics
High Average Low
9.48 %
5.14 %
1.48 %
(March 31, 2007)   (Mar 31 2019)





Financial Statements
Davita Inc 's Assets $ 17,771 million DVA's Balance sheet
Davita Inc 's Income $ 223 million Quarterly DVA's Income Statement
DVA's Income by Division See DVA's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 18.42 % 3.47 % 0.92 % -0.25 % 1.22 %
Total Assets in million 17,637 14,894 14,395 14,264 14,301
Y / Y Net Income Change -13.75 % 30.7 % 22.43 % -35.5 % 21.82 %
Net Income in million 1,079 1,251 957 782 1,212
Annual Return On Assets 6.12 % 8.4 % 6.65 % 5.48 % 8.47 %

DVA's 5 Years Annual ROA >> Back to DVA Management Effectiveness >> Compare DVA ROA to its Competitors



Comment on DVA's ROA in the fiscal year ending 2025
In the fiscal year 2025 Davita Inc 's ROA decreased compared to previous year to 6.12 %, due to deterioration of net income -13.75 % to $1,078.72 million, from $1,250.74 million a year ago, as DVA's assets were $17,637.35 million.


More Return On Assets Ratios
DVA's' Return on Assets at Yahoo Finance
Healthcare Facilities Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DVA's Roa Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DVA's Competitors
Subscribers only: Roa for Davita Inc 's Suppliers
Subscribers only: Return On Assets for DVA's Customers

You may also want to know
DVA's Roi DVA's Inventory Turnover Ratio DVA's Growth Rates DVA's Dividend Comparisons
DVA's Profitability Ratios DVA's Asset Turnover Ratio DVA's Dividend Growth
DVA's Roe DVA's Valuation Ratios DVA's Financial Strength Ratios DVA's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector ROA
Corcept Therapeutics Inc  18.09 %
Chemed Corporation  17.73 %
Halozyme Therapeutics Inc   17.26 %
Pro dex Inc   16.75 %
Denali Therapeutics Inc   16.42 %
Krystal Biotech Inc   15.48 %
West Pharmaceutical Services Inc   15.47 %
Dexcom Inc   15.47 %
Intuitive Surgical Inc   14.71 %
Vertex Pharmaceuticals Inc  14.16 %
Neurocrine Biosciences Inc   13.69 %
Illumina Inc   13.43 %
Healthcare Services Group Inc   12.79 %
Kiniksa Pharmaceuticals International Plc  12.64 %
Tenet Healthcare Corp  12.39 %
Hca Healthcare Inc   11.73 %
Carlisle Companies Incorporated  11.72 %
Regeneron Pharmaceuticals Inc   11.50 %
Lantheus Holdings Inc   11.43 %
Msa Safety Inc  11.01 %
Encompass Health Corporation  10.99 %
Inspire Medical Systems inc   10.89 %
Transmedics Group Inc   10.67 %
Bristol myers Squibb Company  10.47 %
Lemaitre Vascular Inc   10.28 %
Bio rad Laboratories Inc   9.88 %
3m Company  9.60 %
Bioventus Inc   9.47 %
Medinotec Inc   8.67 %
Tactile Systems Technology Inc   8.53 %

Date modified: 2026-10-30T13:08:25+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.